The decreased expression of miR-101 correlated with the pathogenesis and prognosis of DLBCL, while upregulation of miR-101 in DLBCL inhibited cell proliferation and facilitated apoptosis by targeting MEK1 [65]. The gene discussed is MAP2K1; the disease is diffuse large B-cell lymphoma.